Posted by Michael Wonder on 06 Mar 2024
NICE publishes final draft guidance on Enhertu after commercial discussions conclude without a price to make it a cost-effective use of NHS resources
6 March 2024 - NICE has published final draft guidance that does not recommend Enhertu (trastuzumab deruxtecan; Daiichi Sankyo) for treating advanced HER2 low breast cancer in adults.
The decision follows the conclusion of negotiations between NHS England and the company that sought to agree a commercial arrangement to make Enhertu available at a cost-effective price for the NHS.
